S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
Log in

NASDAQ:XOMAXOMA Stock Price, Forecast & News

$18.18
-0.90 (-4.72 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$17.93
Now: $18.18
$19.37
50-Day Range
$18.18
MA: $21.16
$23.30
52-Week Range
$14.14
Now: $18.18
$28.85
Volume63,900 shs
Average Volume58,818 shs
Market Capitalization$200.25 million
P/E RatioN/A
Dividend YieldN/A
Beta1.16
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Read More
XOMA logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:XOMA
CUSIP98419J10
Phone510-204-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.37 million
Book Value$5.03 per share

Profitability

Net Income$-1,980,000.00
Net Margins-102.32%

Miscellaneous

Employees11
Market Cap$200.25 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

XOMA (NASDAQ:XOMA) Frequently Asked Questions

How has XOMA's stock been impacted by COVID-19 (Coronavirus)?

XOMA's stock was trading at $19.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, XOMA stock has decreased by 6.8% and is now trading at $18.18. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of XOMA?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for XOMA.

When is XOMA's next earnings date?

XOMA is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for XOMA.

How were XOMA's earnings last quarter?

XOMA Corp (NASDAQ:XOMA) announced its earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.33. The biotechnology company earned $0.80 million during the quarter, compared to the consensus estimate of $3.40 million. XOMA had a negative return on equity of 34.27% and a negative net margin of 102.32%. View XOMA's earnings history.

What price target have analysts set for XOMA?

2 brokerages have issued 1 year price targets for XOMA's stock. Their forecasts range from $29.00 to $30.00. On average, they anticipate XOMA's share price to reach $29.50 in the next year. This suggests a possible upside of 62.3% from the stock's current price. View analysts' price targets for XOMA.

Has XOMA been receiving favorable news coverage?

Press coverage about XOMA stock has trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. XOMA earned a news sentiment score of -1.5 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about XOMA.

Who are some of XOMA's key competitors?

What other stocks do shareholders of XOMA own?

Who are XOMA's key executives?

XOMA's management team includes the following people:
  • Mr. James R. Neal, CEO & Director (Age 63)
  • Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 45)
  • Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 43)
  • Dr. Deepshikha Datta, Chief Bus. Officer

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

How do I buy shares of XOMA?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $18.18.

How big of a company is XOMA?

XOMA has a market capitalization of $200.25 million and generates $18.37 million in revenue each year. The biotechnology company earns $-1,980,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. XOMA employs 11 workers across the globe.

What is XOMA's official website?

The official website for XOMA is www.xoma.com.

How can I contact XOMA?

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.